PL1830872T3 - Białka fuzyjne - Google Patents

Białka fuzyjne

Info

Publication number
PL1830872T3
PL1830872T3 PL05810103T PL05810103T PL1830872T3 PL 1830872 T3 PL1830872 T3 PL 1830872T3 PL 05810103 T PL05810103 T PL 05810103T PL 05810103 T PL05810103 T PL 05810103T PL 1830872 T3 PL1830872 T3 PL 1830872T3
Authority
PL
Poland
Prior art keywords
fusion proteins
fusion
proteins
Prior art date
Application number
PL05810103T
Other languages
English (en)
Inventor
Keith Foster
John Chaddock
Philip Marks
Patrick Stancombe
K Roger Aoki
Joseph Francis
Lance Steward
Original Assignee
Sec Dep For Health
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0426394A external-priority patent/GB0426394D0/en
Application filed by Sec Dep For Health, Allergan Inc filed Critical Sec Dep For Health
Publication of PL1830872T3 publication Critical patent/PL1830872T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
PL05810103T 2004-12-01 2005-12-01 Białka fuzyjne PL1830872T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0426394A GB0426394D0 (en) 2004-12-01 2004-12-01 Fusion proteins
GB0504964A GB0504964D0 (en) 2004-12-01 2005-03-10 Fusion proteins
PCT/GB2005/004585 WO2006059093A2 (en) 2004-12-01 2005-12-01 Fusion proteins
EP05810103A EP1830872B1 (en) 2004-12-01 2005-12-01 Fusion proteins

Publications (1)

Publication Number Publication Date
PL1830872T3 true PL1830872T3 (pl) 2011-09-30

Family

ID=35745992

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05810103T PL1830872T3 (pl) 2004-12-01 2005-12-01 Białka fuzyjne

Country Status (5)

Country Link
EP (1) EP1830872B1 (pl)
AU (1) AU2005311086B2 (pl)
CA (1) CA2595115C (pl)
PL (1) PL1830872T3 (pl)
WO (1) WO2006059093A2 (pl)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
ATE348178T1 (de) 1999-08-25 2007-01-15 Allergan Inc Aktivierbare rekombinante neurotoxine
US7138127B1 (en) 2000-01-19 2006-11-21 Allergan, Inc. Clostridial toxin derivatives and methods for treating pain
DE602005011458D1 (de) 2004-09-01 2009-01-15 Allergan Inc Abbaubare clostridientoxine
US8512984B2 (en) 2004-12-01 2013-08-20 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8603779B2 (en) 2004-12-01 2013-12-10 Syntaxin, Ltd. Non-cytotoxic protein conjugates
US8399400B2 (en) 2004-12-01 2013-03-19 Syntaxin, Ltd. Fusion proteins
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
US8778634B2 (en) 2004-12-01 2014-07-15 Syntaxin, Ltd. Non-cytotoxic protein conjugates
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
AU2006227816B2 (en) 2005-03-15 2012-04-05 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
US8021859B2 (en) 2005-03-15 2011-09-20 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
ATE518882T1 (de) * 2005-09-19 2011-08-15 Allergan Inc Mit clostridientoxin aktivierbare clostridientoxine
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
AU2011202219B2 (en) * 2005-12-01 2015-05-28 Allergan Inc. Fusion proteins
AU2011202225B2 (en) * 2005-12-01 2015-08-20 Allergan, Inc. Non-cytotoxic protein conjugates
GB0610867D0 (en) * 2006-06-01 2006-07-12 Syntaxin Ltd Treatment of pain
US10792344B2 (en) 2006-06-29 2020-10-06 Merz Pharma Gmbh & Co. Kgaa High frequency application of botulinum toxin therapy
AR061669A1 (es) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa Aplicacion de alta frecuencia de terapia con toxina botulinica
WO2008105901A2 (en) 2006-07-11 2008-09-04 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
AU2007272515B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
US20090104234A1 (en) * 2007-10-23 2009-04-23 Allergan, Inc. Methods of treating chronic neurogenic inflammation using modified clostridial toxins
MX2010004502A (es) * 2007-10-23 2010-06-17 Allergan Inc Metodos para tratar trastornos neurologicos urogenitales usando toxinas clostridiales modificadas.
CA2727082C (en) * 2008-06-12 2019-02-26 Syntaxin Limited Fusion proteins for use in suppression of acromegaly
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
CN102083451A (zh) * 2008-06-12 2011-06-01 赛恩泰新公司 癌症的抑制
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN105833254A (zh) 2008-12-10 2016-08-10 阿勒根公司 梭菌毒素药物组合物
KR101923847B1 (ko) 2009-03-13 2018-11-29 알러간, 인코포레이티드 면역 기반 재표적화된 엔도펩티다제 활성 검정
US20100303757A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US20100303794A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
CN102574899A (zh) * 2009-08-14 2012-07-11 阿勒根公司 使用胰高血糖素样激素再靶向内肽酶治疗癌症的方法
CN102573876A (zh) 2009-08-14 2012-07-11 阿勒根公司 使用甘丙肽再靶向内肽酶治疗癌症的方法
EP2464366A2 (en) 2009-08-14 2012-06-20 Allergan, Inc. Methods of treating cancer using growth factor retargeted endopeptidases
CA2771154A1 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using opioid retargeted endpeptidases
AU2010282276A1 (en) 2009-08-14 2012-03-15 Allergan, Inc. Methods of treating cancer using neurotrophin retargeted endopeptidases
WO2011020114A2 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using tachykinin retargeted endopeptidases
SG181772A1 (en) * 2009-12-16 2012-07-30 Allergan Inc Modified clostridial toxins comprising an integrated protease cleavage site-binding domain
US20120207733A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases
WO2012112422A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using growth factor retargeted endopeptidases
WO2012112432A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Methods of inhibiting aberrant blood vessel formation using opioid retargeted endopeptidases
WO2012112434A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
WO2016110662A1 (en) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
KR102480965B1 (ko) 2016-09-13 2022-12-26 알레간 인코포레이티드 안정화된 비단백질 클로스트리듐 독소 조성물
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
KR20230155007A (ko) 2021-03-30 2023-11-09 입센 바이오팜 리미티드 통증 ＆ 염증성 장애의 치료를 위한 촉매 불활성 클로스트리디움 신경독소
JP2024513191A (ja) 2021-03-30 2024-03-22 イプセン バイオファーム リミテッド 疼痛及び炎症性障害の処置
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
CN115927263A (zh) * 2022-12-13 2023-04-07 中国药科大学 一种IgA蛋白酶及其制备方法
GB202318884D0 (en) 2023-12-11 2024-01-24 Ipsen Biopharm Ltd Formulation

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
DE19642043A1 (de) 1995-10-23 1997-04-24 Hexal Ag Transdermales therapeutisches System (TTS) für die Verabreichung von Wirkstoffen zur Behandlung von Drogenabhängigkeit oder Drogensucht
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US6641820B1 (en) * 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
ITMI20022022A1 (it) * 2002-09-24 2004-03-25 Girolamo Calo' Analoghi di nocicettina.
GB0321344D0 (en) 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates

Also Published As

Publication number Publication date
AU2005311086A1 (en) 2006-06-08
WO2006059093A3 (en) 2006-08-17
EP1830872A2 (en) 2007-09-12
WO2006059093A2 (en) 2006-06-08
CA2595115C (en) 2014-01-21
EP1830872B1 (en) 2010-11-17
CA2595115A1 (en) 2006-06-08
AU2005311086B2 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
PL1830872T3 (pl) Białka fuzyjne
GB0426397D0 (en) Fusion proteins
IL176894A0 (en) Albumin fusion proteins
IL189246A0 (en) Albumin fusion proteins
EP1934372A4 (en) SSB-POLYMERASE HYBRID PROTEINS
ZA200801224B (en) Albumin fusion proteins
GB0423974D0 (en) Proteins
GB0417887D0 (en) Protein
GB0426399D0 (en) Fusion proteins
GB0423002D0 (en) Proteins
GB0401882D0 (en) Protein
GB0404929D0 (en) Protein
GB0416035D0 (en) Protein
GB0411678D0 (en) Proteins
GB0405643D0 (en) Proteins
GB0418666D0 (en) Proteins
GB0418248D0 (en) Proteins
GB0415161D0 (en) Proteins
GB0405885D0 (en) Proteins
GB0412570D0 (en) Proteins
AU2005905300A0 (en) Fusion Protein
GB0403742D0 (en) Protein
GB0408439D0 (en) Protein
GB0402811D0 (en) Protein
GB0402662D0 (en) Protein